Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody
injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks
for 52 week